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1. Introduction  
The purpose of this chapter is to review the tissue-specific role of estrogen (E2) and 
progesterone (P4) in human endometrium and mammary gland. It is well known that both 
E2 and P4 are essential for the development and differentiation of human endometrium and 
mammary gland, but the exact basis for differential tissue-specific signalling of E2 and P4 
are still not fully understood. This chapter explores observed functions of two major female 
steroid hormones and their cognate receptors in normal physiology of human reproductive 
system but also in assisted reproductive technology and breast cancer treatment. 
The normal reproductive physiology requires tightly coordinated action of hypothalamus, 
pituitary gland, ovaries and endometrium. Also functioning of other endocrine units such as 
the thyroid and adrenal glands are essential for regular ovulation and cyclic changes. The 
production of ovarian steroid hormones is coordinated by the hypothalamic-pituitary-
gonadal axis which is activated in puberty (Figure 1). The hypothalamus produces and 
secretes luteinizing hormone-releasing hormone (LHRH), which binds to its receptors in 
pituitary gland. This causes cascade of biochemical events culminating in the production of 
two hormones in pituitary gland, luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH). LH and FSH are secreted into the general blood circulation and attach to 
receptors on the ovary, where they trigger ovulation and stimulate the production of E2 and 
P4. Ovarian steroid hormones themselves have direct role in the development of the inner 
lining of the uterus but they also act as a positive feedback system to hypothalamus and 
pituitary gland for continuous cyclic changes until the beginning of menopause (Kanis and 
Stevenson, 1994). 
Cholesterol is the building block for all steroid hormones, which is carried into the 
bloodstream and through a sequence of enzymatic changes is synthesized into final 
products. In the bloodstream steroid hormones are distributed rapidly throughout the 
tissues and act on distant targets. This secretory process is called endocrine action and the 
function of many target tissues as mammary gland, brain, bones, liver and heart are affected 
by circulating hormones. Steroid hormones can also act very close to their site of secretion 
www.intechopen.com
 Steroids – Basic Science 
 
36
 
Fig. 1. The female hypothalamic–pituitary–gonadal axis. The hypothalamus produces and 
secretes luteinizing hormone–releasing hormone (LHRH) into a system of blood vessels that 
link the hypothalamus and the pituitary gland. LHRH stimulates the pituitary gland by 
attaching to specific molecules (i.e., receptors). After the coupling of LHRH with these 
receptors, a cascade of biochemical events causes the pituitary gland to produce and secrete 
two hormones, luteinizing hormone (LH) and follicle–stimulating hormone (FSH). LH and 
FSH are two of a class of hormones commonly known as gonadotropins. They are secreted 
into the general circulation and attach to receptors on the ovary, where they trigger 
ovulation and stimulate ovarian production of the hormones estrogen and progesterone. 
These female hormones cause monthly menstrual cycling and have multiple effects 
throughout the body. In particular, estrogen has profound effects on the skeletal system and 
is crucial to maintaining normal bone health (Figure adapted from Kanis and Stevenson, 
1994). 
on adjacent cells and tissues as it happens in gonads, testis and ovaries- paracrine action.  
Gonads produce only three classes of steroids: progestins, androgens and estrogens where 
progestins are obligatory precursors of both androgens and estrogens. Likewise, androgens 
are obligatory precursors of estrogens. Steroidogenesis in the ovary is compartmentalized in 
a cell-specific manner: the theca cells primarily producing androstenedione and the 
granulosa cells completing the synthesis of E2. After the ovulation the corpus luteum of the 
ovary starts to produce P4. Albeit the vast amount of sex steroids are synthesized locally in 
peripheral tissue, providing individual target tissues with the means to adjust synthesis and 
metabolism to their local requirements (Venken et al.,  2008). 
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Beside the reproductive system, one of the most widely recognized effects of E2 is the 
prevention of the osteoporosis. Adequate E2 levels through E2 replacement therapy has 
shown to prevent or diminish calcium loss from bones in menopausal women (Venken et 
al., 2008). In the nervous system both estrogens and androgens have been reported to 
influence verbal fluency, performance of spatial tasks, verbal memory capacity and fine 
motor skills (Kelly and Ronnekleiv, 2008). The major role for P4 in humans is related to 
initiation and maintenance of the pregnancy. P4 is essential for milk preparation and 
secretion in mammary gland and for mediating signals required for sexually responsive 
behaviour. Recent evidence also supports a role for P4 in the modulation of bone mass 
(Seifert-Kaluss and Prior, 2010). 
NRs function as transcription factors. The biological activities of E2 and P4 are mediated 
mainly by nuclear receptors (NRs). Binding of a steroid hormone to its cognate receptor 
results in a conformational change in the nuclear receptor that allows the ligand-receptor 
complex to bind with high affinity to response elements in DNA and regulate transcription 
of target genes. In the absence of ligand, NRs are held in a multi-subunit complex containing 
heatshock proteins such as Hsp90, SP70, HSP40, Hop, and p23 (Wolf et al., 2008). After 
binding to ligand, these receptors, undergo conformational changes, dissociate themselves 
from chaperone proteins, dimerize and in some cases translocate into the nucleus (if not 
already locked into the nucleus) (Bain et al., 2007). The differences in specificity of molecular 
mechanisms result from receptor subcellular location and binding to genomic DNA as 
homo- or heterodimers in either head-to-tail or head-to-head orientation to different 
consensus sequences known as hormone response elements (HREs) (Bain et al., 2007). Upon 
NR activation a hydrophobic pocket is created in their tertiary structure for interaction with 
co-activators such as members of the steroid receptor co-activator (SRC) protein family or 
co-repressors such as NR co-repressor (NCoR) and silencing mediator for retinoic acid and 
thyroid hormone receptor (SMRT) ( Hall et al., 2005). The recruitment of co-regulators leads 
to alterations in the rate of gene expression via modification of initiation complex formation 
process. Two types of estrogen receptors, ER┙ and ER┚, encoded by separate genes, are 
found in humans (Enmark etal., 1997; Kuiper and Gustafsson, 1997).  P4 signalling is also 
mediated by two receptors, PRA and PRB, which are encoded by the same gene but 
transcribed from different promoters, resulting in a PRB that has an additional 164 amino 
acids at the N-terminus (Wen et al., 1994; Kastner et al., 1990). PRB is a stronger 
transcriptional activator in most cell types, while PRA acts often as a dominant negative 
repressor for PRB activity (Tung et al., 1993; Vegeto et al., 1993). 
In addition to operating as TFs in the nucleus, NRs have been shown to possess non-
genomic action which is usually characterized by a shorter lag time required to elicit a 
biological response following steroid hormone stimulation. For instance ERs can regulate 
gene expression independent of estrogen responsive element (ERE) through tethering 
different TFs and by membrane- initiated ER interference with other intracellular pathways. 
Examples of motifs recognized by ER other than ERE is the activator protein-1 site (AP-1 
site) commonly occupied by the TFs c-Fos/c- Jun B (Björnström and Sjöberg., 2004). 
2. The role of E2 and P4 in human endometrium  
Human endometrium is the inner tissue lining of uterine cavity that undergoes monthly 
cyclic changes dictated by ovarian steroid hormones E2 and P4 (Figure 2). As endometrium 
is a regenerative tissue it is subjected to proliferation, secretion and degeneration on 
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monthly basis. Nearly all morphologic and biochemical processes that the uterus undergoes 
during its acquisition of receptivity are directly or indirectly regulated by ovarian steroid 
hormones (Lim et al., 2002). The development of human endometrium is divided into 
follicular and luteal phase. During the follicular phase ovarian E2 is produced with 
increasing quantities until ovulation, stimulating the proliferation and growth of the 
epithelial and stromal components of the endometrium. During the luteal phase the 
increasing amounts of the P4 and secondary maintaining levels of E2 are both involved in 
the differentiation of the endometrium but P4 reverses the proliferative effects of E2 (Lim et 
al., 2002). Together, coordinated action of steroid hormones produced by the follicle and 
corpus luteum prepare the endometrium every month for potential embryo implantation. In 
the event of embryo implantation P4 predominantly facilitates and permits decidualization 
of the endometrium and supports maintenance of pregnancy. On the contrary, in the 
absence of implantation declining levels of E2 and P4 lead to degeneration of the 
endometrial tissue, which is followed by regeneration during the next cycle. In addition to 
cell differentiation, P4 plays the key role in the decision of cell survival or death prior to the 
menstruation. Three proteins related to apoptotic activation in endometrial cells are proto-
oncogene p53, FOXO1 (forkhead box-O) and BIM which act as a switches between apoptosis 
and survival (Brosens and Gellersen, 2006). 
 
 
Fig. 2. E2 and P4 in human endometrium. E2 causes the growth or proliferation of the 
endometrium during the first two weeks of the menstrual cycle. After ovulation, the corpus 
luteum produces P4. This hormone causes the endometrial glands to secrete nutritive 
substances required by the embryo and to allow it to implant into the endometrial lining 
(figure adapted from internet http://www.tubal-reversal.net/uterus-menstrual-cycle.htm). 
Ovarian steroids mediate their signals through genomic or non-genomic pathways.  The 
genomic signal is passed on by cognate receptors, ERs and PRs, in endometrial cells. As E2 
is dominant hormone during the follicular phase of the cycle genes regulated by E2 are also 
more often related to tissue proliferation. Under the actions of E2 the epithelial cells respond 
by rapid induction of gene expression that promotes DNA synthesis and cell replication 
(Lessey et al., 2010). During the luteal phase P4 induces the genes related to differentiation. 
Clinically used steroid hormone analogues (Tamoxifen, Fluvestrant, Progestin, 
Mifepristone) could have a suppressive or repressive impact on normal steroid hormone 
signalling in endometrial cells (Figure 2). The expression of ERs and PRs in spatiotemporal 
manner is crucial for the successful implantation process (Lessey et al., 2003). Although ER┙ 
www.intechopen.com
The Tissue Specific Role 
of Estrogen and Progesterone in Human Endometrium and Mammary Gland 
 
39 
and ER┚ are present in all endometrial cell types throughout the entire menstrual cycle, they 
are expressed at higher levels during the proliferative phase and show lower activity during 
the secretory phase because of the suppressive effect of P4. After the proliferative phase P4 
takes the E2-primed endometrium towards a state of receptivity. P4, acting through its 
cognate receptors, is absolutely mandatory for successful implantation and post-
implantation embryo survival. PRA and PRB levels are similar during the follicular phase of 
the menstrual cycle while the PRA is down-regulated at the time of implantation but higher 
stromal PRB levels during the mid-luteal phase have been reported (Arnett-Mansfield et al., 
2004). The expression of the PR gene in endometrial glands is controlled by E2 and P4, 
where E2 induces PR synthesis and P4 down-regulates the expression of its own receptor 
(Graham et al., 1990). The actions of P4 counter the effects of P4 in the endometrium through 
paracrine regulators from the stromal part. Recent studies about small non-protein coding 
RNAs (microRNA, miRNA) have revealed their important role in gene regulation in 
endometrium (Kuokkanen et al., 2010; Li et al.,  2011). The regulation  of specific microRNAs 
is a mechanism that appears to fine tune gene expression by blocking cell proliferation at the 
time of implantation P4 dependently (Lessey et al., 2010). 
 
 
Fig. 3. E2 and P4 genomic signalling in human endometrial cell. E2 produced by ovary 
enters into the cell and binds to its specific receptors ER┙ or ER┚. Formed complex moves 
into the cell and has an impact on target gene expression. After the ovulation corpus luteum 
starts to produce P4 which also diffuses into the endometrial cells and through its receptors 
regulate gene expression.  Steroid hormone analogues (Tamoxifen, Fluvestrant, Progestin, 
Mifepristone) have a suppressive or repressive impact on ER , PR signalling.  
2.1 Endometrial gene expression during the time of embryo implantation  
In a restricted period, called implantation window (IW), endometrium is most receptive for 
the embryo attachment. In humans IW is temporally confined to days 20-24 of menstrual 
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cycle (8-10 days after ovulation). During this time period corpus luteum induces high level 
of P4 and stable level of E2 expression. For successful pregnancy the apposition, adhesion 
and invasion of developing embryo is needed which can only happen if the endometrium is 
at the right developmental stage posessing a receptive atmosphere.   
There is a certain group of women who repeatedly fail to achieve pregnancy in spite of good 
quality embryos transferred during IVF (in vitro fertilisation) treatments. This has led to the 
search for better solutions to improve implantation rates. In a molecular level embryo 
implantation is a dialog between blastocyst and receptive endometrium which is mediated 
by various growth factors, cytokines, lipid mediators, transcription factors and other 
putative molecules often regulated by steroid hormones. In recent years, numerous studies 
applying global gene expression analysis have found a wide range of genes up- or down 
regulated in human endometrium during the IW (Carson et al., 2002; Kao et al., 2002; 
Riesewijk et al., 2003; Horcajadas et al., 2004; Krikun et al., 2005; Mirkin et al., 2005; Simon et 
al., 2005; Punyadeera et al., 2005; Talbi et al., 2006;  Horcajadas et al.,  2008; Haouzi et al., 
2009a,b; Altmäe et al., 2010). Each study has brought out candidate genes believed to be 
crucial in embryo implantation process but the overlap of potential marker genes between 
different publications has still remained relatively low. However, today there are already 
some biomarkers confirmed in separate studies which are pivotial during implantation 
process. For example, the most potential endometrial marker identified is leukemia 
inhibitory factor (LIF) and its importance has been proven in animal and human studies 
(Stewart et al., 1994; Arici et al., 1995; Steck et al., 2004). Unfortunately, the development of 
recombinant human LIF (r-fLIF) has not met the expectations of increasing implantation 
rates in infertile women (Brinsden et al., 2009). The localization of immune system related 
molecules like cytokines, IL-6 and IL-11, has been identified in endometrial cells and they 
have shown coincidental expression changes at the time of high levels of E2 and P4 
(Tabibzadeh et al.,  1995; Robertson et al., 2000; Vandermolen and Gu, 1996; Cork et al., 2001; 
Dimitriadis et al., 2000; von Rango et al., 2004). The two integrins, ┙4┚l and ┙v┚3, appear to 
be good markers of the receptive endometrium in normal fertile women (Lessey et al., 1994). 
Recognized growth factors related to endometrial receptivity and implantation are 
transforming growth factor ┚ (TGF-┚), epidermal growth factor (EGF), heparin binding-
epidermal growth factor (HB-EGF) and inlsulin like growth factor (IGF) (Jones et al., 2006b; 
Hofmann et al., 1991; Dadi et al., 2007; Lessey et al., 2002; Stavreus-Evers et al., 2002). 
Growth factors and their respective receptors have shown to enhance embryo development 
and improve implantation rates in IVF cycles (Kabir-Salmani et al., 2004). 
It is more likely that there is no single molecule, which could solve the implantation issue 
and help patients with recurrent implantation failures. As a complex process implantation 
seems to depend on many factors, which influence the development of the embryo and 
endometrial dating in synchronized manner. Moreover, the individual differences and 
monthly cyclic changes of the regenerative tissue make the search for universal markers 
relevant to implantation complex. 
2.2 The influence of the IVF treatment on endometrial receptivity  
Since the first announcement of successful IVF treatment in 1978 (Steptoe and Edwards, 
1978) assessed fertilization procedures have been increasingly used world-wide. Based on 
the report by European Society of Human Reproduction and Embryology (ESHRE) in 2008, 
more than three million babies have been born with the help of IVF (ESHRE 2008). 
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Nowadays the number of couples seeking for aid to achieve pregnancy is constantly 
increasing as at least every tenth couple requires infertility treatments.   
Ovarian stimulation and ovulation induction with gonadotrophin administration has been a 
success from the 1960s (Fowler and Edwards, 1957). Ovulation induction leads to multi-
follicular growth instead of a single follicle in natural cycles escalating possible successful 
fertilisation. Still, the general success rates for clinical pregnancies have stayed around 30-
40% for more than three decades (Department of Health and Human Services Centres for 
Disease Control and Prevention Report 2001). The focus to develop more effective ovarian 
stimulation protocols to increase the number of oocytes and embryos obtained from one 
cycle has by some means overlooked the relevance of supraphysiological levels of ovarian 
steroid hormones and their collateral effect on the endometrium (Simon et al., 2008). In 
modern IVF, drugs used to stimulate ovaries during the follicular phase include clomiphene 
citrate, urinary and recombinant gonadotrophins and gonadotrophin releasing hormone 
(GnRH) agonists and antagonists (Edwards et al., 2005). The usage of ovarian stimulating 
drugs often results in shorter luteal phase of the endometrium, which is therefore no longer 
synchronized with embryo development. The use of GnRH agonists may have a negative 
effect on implantation. Several studies observing endometrial biopsies from patients 
undergoing IVF treatment show 1-3 day advancement in endometrial development (Lass et 
al., 1998; Nikas et al 1999). The formation of pinopodes, considered as morphological 
markers for receptive endometrium, has also been shifted to day 17 or 18 compared to day 
20 in normal cycle (Stavreus-Evers et al., 2001). Elevated concentrations of E2 and subtle P4 
increases in the late follicular phase lead to modulated steroid hormone receptor profile 
(Papanikolau et al., 2005).  Histological study has shown down-regulation of the ERs and 
PRs and pinopode expression in stimulated cycles compared to natural cycles (Develioglu et 
al., 1999). There is some evidence of a negative impact of supraphysiological steroid levels 
on endometrium because increased pregnancy rates have been observed in the presence of 
reduced production of serum E2. This explains the fact that there are higher pregnancy and 
implantation rates recorded for oocyte recipients versus donors who have only P4 support 
prior to embryo transfer (Check et al., 1995). A premature reduction in PRs in the early luteal 
phase has been found after ovarian stimulation. Horcajadas and colleagues have demonstrated 
that gene expression profiling of the endometrium is different between natural and controlled 
ovarian stimulation cycles in the receptive phase (Horcajadas et al., 2008). 
There are ways to restore the length of luteal phase by stimulating corpus luteum with hCG or 
by supplementing the luteal phase with steroids, such as E2 and P4 (Smitz et al., 1992). Also, to 
overcome the side effects caused by high doses of drugs milder stimulation protocols have 
been developed (Olivennes et al., 2002; Nargund and Frydman, 2007; Pennings and Ombelet, 
2007; Ubaldi et al., 2007). The evidence regarding a potentially negative effect of 
supraphysiological steroid levels on endometrial receptivity (Simon et al., 1995; Devroey et al., 
2004), corpus luteum function (Fauser and Devroey, 2003; Beckers et al., 2006), oocyte and 
embryo quality (Valbuena et al., 2001; Baart et al., 2007) indicate that limited ovarian 
stimulation and response might have a beneficial effect on implantation potential. 
2.3 E2 and P4 endometriosis  
The ovarian steroid hormones play also a central role in pathogenesis of several uterine 
disorders, including endometriosis, which is characterized by the presence of endometrial 
tissue outside the uterine cavity like the peritoneum and ovary. It has been shown that both 
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eutopic and ectopic endometrial tissues expresses ERs and PRs and they respond to ovarian 
steroid hormones but the predominance of ER┙ and PRA receptors have been described in 
cases of ectopic lesions (Matsuzaki et al., 2001; Attia et al., 2000). Despite the obvious 
importance of E2/P4 in the development of the endometriosis, the exact aetiology and 
pathogenesis of it are still unclear. It is predicted that in general endometriosis could affect 
about 10% of women of reproductive age and up to 25-50% of women seeking infertility 
treatment. There is still uncertainty whether the decreased fertility is related to reduction of 
the oocyte/embryo quality or dysregulation of the endometrium (Kim et al., 2007). Aberrant 
gene expression in endometrium which is suboptimal for implanting blastocyst has been 
shown by several studies in cases of endometriosis (Giudice et al., 2002; Kao et al., 2003). 
Even though endometriosis has been characterized as E2-dependent gynaecological disease, 
where E2 favours the growth of the tissue, the dysregulation of the P4 response on the 
molecular level is suggested in endometriosis. It has been noticed that endometriotic tissue 
does not respond to P4 as normal endometrium does. Altered PR expression or diminished 
activity predictably results in differential gene expression compared to eutopic tissue 
(Cakmak et al., 2010). For example, altered P4 signalling can cause unpaired regulation of 
HOXA 11, HOXA12 genes in ectopic tissue which are expressed in high levels during the IW 
in normal tissue (Cakmak et al., 2010). The up-regulation of HOXA10 and HOXA11 
expression fails to occur in women with endometriosis (Taylor et al., 1999). Recent studies 
looking for functional miRNA-s have shown up-regulation of miR-21 in eutopic 
endometrium of women with versus without endometriosis (Luo et al., 2010; Aghajanova et 
al., 2011). 
Hopefully further studies in the future help us understand the molecular mechanisms, 
which are responsible for the development of endometriosis. 
3. The role of E2 and P4 in mammary gland  
The development and physiology of human mammary gland is also under the strict control 
of steroid hormones, including E2 and P4. The mammary gland is not completely formed at 
birth, but begins to develop in early puberty when the primitive ductal structures enlarge 
and branch (Russo et al., 1987). From that point ovarian E2 and P4 are fundamental for the 
growth and differentiation of the duct system. There are slight cyclical changes during each 
menstrual cycle caused by ovarian steroid hormones where E2 is increasing the volume of 
the tissue and P4 is responsible of the acinar growth of breast tissue. During pregnancy, the 
mammary gland epithelium experiences its greatest and most rapid proliferation initially as 
a response to the hormones produced by corpus luteum, following by placental hormones. 
Due to difficulties in studying developing mammary gland there is relatively small amount 
of information about normal ER and PR expression in breast tissue. It has been confirmed 
that PRs and ERs are found in a minority population (7–10%) of luminal, non-dividing 
epithelial cells. As E2 is required to induce progesterone receptor (PR) expression it is 
difficult to separate the effects of P4 alone from E2. However, the obligate role of the ERs 
and PRs in mammary gland development has been confirmed with knocked out mice 
studies (Bocchinfuso and Korach, 1997; Humphreys et al., 1997). 
3.1 E2 and P4 in breast cancer development  
Broad spectrum of physiological activity of steroid hormones displays its dark side in cases 
when cells in steroid hormone guided organs lose their normal responsiveness to hormone. 
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Third of female malignancies are hormone dependent in their growth. Most prominent 
leading death causing factors for women under age of 50 are breast cancer and also various 
cancers of reproductive system. Many factors are involved in the development of breast 
cancer, including genetics, lifestyle, diet, endogenous hormone status and environment. 
Demographic risk factors for breast cancer are early age of menarche, nulliparity, late full-
term pregnancy, higher social class and increasing age. Known factors with protective 
effects on breast cancer development are early full-term pregnancy, increasing number of 
births, longer periods of anovulation and more physical activity (Bernstein et al., 1994). The 
incidence of this lethal cancer has steadily increased during the last centuries in part due to 
the better and more widespread screening procedures. Increased ER┙ expression is one of 
the earliest changes occurring in the tumorigenic process and is associated with 
uncontrolled proliferation of the breast tissue (Khan et al., 1994). Some data is showing that 
ER┚ could negatively modulate the effects of ER┙ but the prognosis for endocrine therapy 
are still under the question because of the somehow contradictory outcomes (Roger et al., 
2001; Speirs et al., 2002). Similarly PR isoform ratio also seems to have a role in breast 
tumorigenesis as the ration of PRA and PRB has been altered with PRA prevalence (Mote et 
al., 2002). 
Currently, only the expression level of ER┙ is measured for clinical decision-making and 
treatment of breast cancer patients as a favourable prognosis in primary tumours. Still, only 
50% of ER┙-positive tumours respond well to hormonal therapy. Large research programs 
are dedicated to search for better and more specific clinical breast cancer markers. The 
significance of ER┚ status is still controversial and further analysis of the role it plays in the 
pathogenesis of breast cancer is required. As more experimental information on E2-
mediated signalling accumulates, new possibilities emerge for breast cancer therapy. 
3.2 Selective ER and PR modulators  
Selective ER modulators (SERMs) function through ERs, acting as agonists or antagonists of 
E2 depending on the target tissue and modulate the signal transduction pathway to E2-
responsive genes. The implementation of SERMs in clinical aspects is wide. They are used to 
treat or prevent breast cancer and osteoporosis, to cure ovulatory dysfunction in women but 
also for contraceptive purposes. SERMs have an ability to differently regulate many ER-
regulated genes (Berrodin et al., 2009; Chang et al., 2010). In general, most SERMs have E2 
agonist activity in bone and antagonist activity in the breast, while the activity in the uterus 
varies among the molecules. The tissue specificity depends on various co-activators (CoA) 
and co-repressors (CoR) expressed and recruited in different tissues (Riggs et al., 2003). E2 
binds to either ER┙ or ER┚ and subsequently binds CoA molecules required to form a 
transcription complex at EREs located in the promoter region of estrogen-responsive genes. 
The antiestrogenic action of a SERM results from the inappropriate folding of an ER┙ or ER┚ 
complex that either cannot recruit CoA molecules or instead recruits CoR molecules. This 
programmed change in conformation produces antiestrogen action at specific sites like the 
breast, but estrogen-like effects in the uterus if an excess of CoA molecules is present. 
SERM–ER complexes may initiate gene transcription to produce an estrogen-like effect, by 
forming a protein–protein interaction at fos/jun that activates AP-1 sites (Jordan et al., 2001) 
(Figure 4). Although widely used and with many beneficial effects in treating breast cancer 
SERMs still battle with several side effects where most common is the stimulation of the 
endometrium. 
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Fig. 4. The signal transduction pathways available to E2 or a SERM to initiate gene 
transcription. E2 receptors – ER┙, ER┚, selective ER modulator-SERM, coactivator –CoA, 
corepressor CoR, E2 response element-ERE, activating protein -1-AP-1 (Figure adapted from 
Jordan et al., 2001).  
Tamoxifen (TAM), the first SERM available for clinical use, is regarded as a highly effective 
agent for the prevention and treatment of breast cancer in premenopausal and 
postmenopausal women. TAM has been used in women to treat breast cancer for over 40 
years (Fisher et al., 1998; Fisher et al., 2005). This compound binds with high affinity to ER, 
thereby blocking the action of native E2. Subsequently it inhibits or modifies the interaction 
of ER with DNA, which impedes the transcriptional activation of target genes (Berry et al., 
2005). TAM strongly counteracts E2 effects, including secretion of several growth factors 
and growth controlling enzymes, so that a woman’s own E2 cannot stimulate growth of the 
tumor cells. TAM has been a successful drug especially in treating hormone-responsive 
breast cancer, being one of the main reasons why ER-positive breast cancer patients have a 
better prognosis compared to those with an ER┙-negative breast tumours. Another positive 
effect was noticed when postmenopausal women’s bone density increased after breast 
cancer treatment (Love et al., 1992). One of the most significant side effects of the treatment 
with the TAM appears to be its proliferative effect on the endometrium (estrogen-agonistic 
effect; Buzdar et al., 1998; Bergman et al., 2000). The use of TAM results significant 3.3 fold 
increase of endometrial cancer (Fisher 2005). The repression of the cell proliferation during 
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breast cancer treatment could lead to endometrial cell proliferation later on (Figure 5). 
Endometrial pathologies associated with TAM use include hyperplasia, polyps, carcinomas 
and sarcomas (Cohen et al., 2004). The full mechanism of this paradox remains still 
undiscovered.  
Another well-studied antiestrogen, Raloxifen, has an E2-antagonistic effect similarly to TAM 
but it is reported to have small or no proliferative effect on uterus (Fugere et al., 2000). 
Although Raloxifen was developed initially for breast cancer treatment, its use was 
abandoned in the late 1980s because clinical trials showed no activity in TAM-resistant 
patients (Buzdar et al, 1998). Today, Raloxifen is used specifically to reduce the risk of 
osteoporosis in postmenopausal women at high risk for osteoporosis (Jordan et al., 2001, 
Cohen et al., 2000).  
As SERMs have the ability to provide mixed functional ER agonist or antagonist activity, 
depending on the target tissue, compaunds devoid of agonist activity have been developed. 
The most known „pure“ antiestrogen is Fulverstant (aslo known as ICI 182780) (Bowler et 
al., 1989; Wakeling et al., 1991). In addition to blocking the ER activity Fulvestrant induces 
ER degradation by changing its conformation (Dauvois et al., 1993; Gibson et al., 1991; Reese 
and Katzenellenbogen 1992).  This forces the receptor into conformation that it is recognized 
as being misfolded, which induces its rapid degradation (Wu et al 2005). Fulvestrant is 
currently licensed for the use in postmenopausal women with ER-positive recurrent disease 
(Johnston et al., 2010). However, the lack of agonist activity limits its beneficial effects in 
bone. 
SERM might inhibit the ER found in breast cells but activate the ER present in uterine 
endometrial cells. That would inhibit cell proliferation in breast cells, but stimulate the 
proliferation of uterine endometrial cells (Figure 5). There are number of decision points that 
determine the biological response to a SERM, which is linked to its E2-like ability to recruit 
CoA-s and CoR-s. ER contains a ligand-binding domain, called Activating Function-2 (AF-
2), which is essential for the activation of genes that mediate the E2 effect in tissues like 
breast and uterus. Therefore, the different ligands can induce distinct gene transcription 
processes. For example, the union of the ligand binding domain with TAM results in partial 
agonistic effect in the uterus, whereas the same interaction is fully antagonistic in the breast 
(Perez et al., 2006). 
Similarly to anti-estrogens, anti-progestins or Selective Progesterone Receptor Modulators 
(SPRMs) are developed in order to antagonize the processes activated by P4. Mifepristone 
(RU-486) acts as a P4 antagonist by competing with endogenous P4 for receptor binding and 
has three primary pharmacological effects: endometrial, gonadotropic, and adrenocortical 
(Goldberg et al., 1998). It has 2 to 10 time higher affinity compared to P4 to bind PRs 
(Brogden et al., 1993). Because PRs are found primarily in reproductive organs, Mifepristone 
exerts its principal effect on the uterus. More precisely, Mifepristone blocks the effects of 
natural P4 on the endometrium and decidua. While P4 is supposed to support the 
pregnancy, anti-P4 leads to degeneration and shedding of the endometrial lining, thereby 
preventing or disrupting implantation of the conceptus. Mifepristone also increases both 
uterine production of prostaglandins and uterine sensitivity to the contractile effects of 
prostaglandins, stimulating uterine contractions. It is postulated that Mifepristone acts 
directly on the uterine muscle through an entirely separate mechanism, perhaps by 
increasing gap junctions in the myometrium (Weiss et al., 1993). Tissue culture studies have 
shown that Mifepristone continues to display procontractile effects on the uterus even when 
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the effects of prostaglandins are neutralized (Brogden et al., 1993). Most research and 
clinical experience with Mifepristone involves its use as an aborted material. Several studies 
reported its effectiveness in softening and dilation of the cervix prior to surgical abortion, 
decrease of pain in women with diagnosed endometriosis and in labour inducement 
(Goldberg et al., 1998). In the absence of P4, however, Mifepristone can act as a partial 
agonist (Spitz et al., 1993) and upregulate P4-responsive genes, such as p53, and through 
this possesses a slight anticarcinogenic effect. 
 
 
Fig. 5. The opposite effect of SERM on breast and uterine cell proliferation. SERM might 
inhibit the ER found in breast cancer cells but activate the ER present in uterine endometrial 
cells. A SERM of this type would inhibit cell proliferation in breast cells, but stimulate the 
proliferation of uterine endometrial cells. (Figure adapted from internet:  
http://www.cancer.gov/cancertopics/understandingcancer/estrogenreceptors/page14) 
3.3 The risk for cancer development after IVF treatment  
The impact of infertility and fertility treatments on cancer risk has become more and more 
prevalent since the increasing need to use IVF treatment in current society. Relatively low 
number of studies has been published to investigate the relation between IVF treatment and 
developing cancer risk. The administration of high doses of gonadotrophin analogues 
during the induction of the ovaries and synthetic E2 and P4 preparations in order to support 
the endometrium has raised the question of a possible contribution of supraphysiological 
levels of hormones to the development of breast or other cancer types. Previous studies have 
demonstrated a possible association between infertility treatments and breast cancer for 
women treated with at least six cycles with clomiphene citrate, or within the first year after 
starting IVF (Venn et al., 1995, 2001). Also women who start IVF after the age of 30 appear to 
be at increased risk of developing breast cancer (Katz et al., 2008; Pappo et al., 2008). Other 
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studies have found elevated risk for ovarian cancer too but probably the risk was already 
higher prior to the first IVF (Källen et al., 2005; Kristiansson et al., 2007). However, there are 
publications, which have not found a relation between infertility treatments and any cancer 
development (Potashnik et al., 1999, Doyle et al., 2002; Dor et al., 2002; Lerner-Geva et al., 
2010; Brinton et al., 2004). For example, a case-control study (1380 pairs) showed no risk for 
IVF treatment even among women who carry mutations in breast cancer susceptibility gene 
1 (BRCA1) or BRCA2 gene (Kotsopoulos et al., 2008). The common opinion today is that the 
use of fertility medications does not increase the risk of breast cancer among those with 
family history of BRCA mutations. 
A more recent study, published by Källen and colleagues using Swedish cancer register, 
showed that there was no or significantly low cancer risk among women udergoing IVF 
treatment compared to general population. The study included 24 058 women who had 
been treated with IVF where 1279 women later appeared in the cancer register. For 
comparison, total of 1 394 061 women in the general population were studied as a control 
group where 95 775 women had registered cancer (Källen et al., 2011). 
The phrase “healthy patient effect” has emerged saying that women who choose IVF 
treatment might be more aware of risks or more health conscious at the time of conception 
compared to non-IVF women (Venn et al., 2001). In addition, there are numerous 
confounding factors which could influence the outcome of the study like the age at the time 
of the first IVF cycle or the first delivery, the number of the unsuccessful cycles and the 
follow up time after last IVF treatment. It is obvious that the question needs to be studied in 
more detail involving large number of women and with attention to precise subgroups. 
4. Genome-wide E2 and P4 signalling 
There are hundreds of studies presenting how expression of a single gene could change 
upon E2 or P4 treatment in different cell culture. Knock out studies with transgenic animals 
have confirmed the importance of ERs and PRs in reproductive system and cancer 
development. To understand the broad role of steroid hormones in humans it is mandatory 
to study their action in genome-wide level. Recently, the development of large-scale 
genomic methods to analyse gene expression and factor binding to DNA enable us to study 
steroid hormone dependent gene expression changes and transcription regulation in the 
entire genome. As ERs and PRs are acting as TFs they have an ability to regulate the 
expression of proximal and distal genes by binding hormone responsive elements. 
Chromatin immunoprecipitation (ChIP) analysis has been broadly used for identification TF 
binding regions on DNA. ChIP assay can be followed by polymerase chain reaction (PCR), 
hybridization the probes on a microarray (ChIP-on-chip) or high throughput (HTP)-
sequencing (ChIP-Seq) to establish the genomic regions occupied by a specific TF. To 
understand whether TF binding has a positive or negative impact on gene expression 
microarrays, sequencing (RNA-Seq) and RT-qPCR are commonly used followed to mRNA 
extraction.  
4.1 Genome-wide identification of TF binding regions, ChIP-Seq 
ChIP is a technique for assaying protein-DNA interactions in vivo (Weinmann et al., 2002). 
This analysis allows identifying regions of the genome bound directly to ERs or PRs as well 
as regions bound indirectly via other TFs or co-regulators. During the procedure proteins 
are cross-linked to DNA and the chromatin is thereafter sonicated to small fragments 
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around 150-1000bp depending on which application is used below. After 
immunoprecipitation of protein-DNA complexes, the cross-links are reversed and the DNA 
fragments purified. Extracted DNA could be analyzed with either PCR, ChIP-on-chip or 
direct sequencing. Regions significantly overrepresented in the immunoprecipitated DNA 
relative to control DNA are regarded as epigenetically modified or protein-bound, 
depending on the antibody used (Bock et al., 2008). Computational algorithms are used to 
infer the information from the array data or sequencing output. ChIP has two main 
drawbacks. First and the main problem is the specificity of antibodies used. The second 
problem is aggregation of chromatin that contaminates the purified specific chromatin 
fraction and raises unspecific background of isolated DNA. In case of ChIP-on-chip ChIP-
enriched DNA is spotted on glass slide microarrays (chip) to study how regulatory proteins 
interact with the genome of living cells (Lin Z et al., 2007, Liu et al., 2008). ChIP-on-Chip has 
many modifications such as ChIP-linked target site cloning (Lin Z et al., 2007) and ChIP 
coupled with a DNA selection and ligation (ChIP-DSL) strategy for direct target genes, 
permitting analysis of fewer cells than required by the conventional ChIP-on-chip method 
(Kwon et al., 2007). The ChIP-DSL technology is distinct from the latter assay. Besides it 
being more specific and sensitive, the immunoprecipitated DNA is used to template 
oligonucleotide ligation, instead of being directly amplified for hybridization, which makes 
it possible to bypass incomplete decrosslinking. There is also the paired-end ditag (PET) 
approach, which directly links the 5' terminal tags of genomic sequences with their 
corresponding 3' terminal tags to form PET ditags and concatenates them for efficient 
sequencing (Bock et al., 2008). 
ChIP-Seq is emerging as the method of choice for genome-wide identification of TF binding 
sites. The ChIP-Seq involves immunoselecting an enriched population of transcription 
factor-bound chromatin fragments, which are purified and resolved via next-generation 
sequencing. Today, several DNA sequencing technologies are available - the ABI SOLiD 
platform utilizes oligonucleotide ligation and detection methodology (Dietz and Carroll, 
2008), the sequencing-by-synthesis methods of 454 Life Sciences and Solexa/Illumina 
technology utilize, an emulsion based PCR followed by HTP sequencing and reversible 
terminator sequencing respectively. Also it is possible to sequence on single-molecule 
sequencing platforms such as the HeliScope by Helicos where, fluorescent nucleotides 
incorporated into templates can be imaged at the level of single molecules (Figure 6). A 
typical dataset generated from the Illumina Genome Analyzer yields several million short 
sequence reads with typical length 36-75 bp. These are aligned to a reference genome, and 
the resulting trace read placements are used to infer the locations of transcription factor 
binding in a global fashion. ChIP-seq provides clearly interpretable binding information. 
Even more, compared to ChIP-on-chip data normalization is not an issue because the 
sequencing results in absolute read counts (Barski et al., 2007). Also, the repetitive portion of 
DNA is not a hindrance. One limitation is that the process of mapping tags to the reference 
genome can bias the analysis toward genomic regions with unique and complex sequence 
patterns. This is because short sequencing reads that overlap with low-complexity regions 
or with interspersed repeats stand a higher chance of being discarded for lack of unique 
genomic alignment (Bock et al., 2008). Even though ChIP-seq shares ChIP-on-chip’s 
dependence on high-quality antibodies, the unparalleled throughput makes ChIP-seq 
superior for whole genome mapping of DNAprotein interactions. The latest results show 
that ChIP-Seq method could detect more than 10 000 binding regions for ER┙ in MCF7 cells 
(Carroll et al., 2006; Hurtado et al., 2011). Nevertheless, linking the binding regions to the 
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Fig. 6. ChIP followed by highthroughput sequencing. The ChIP process enriches the 
crosslinked proteins or modified nucleosomes using an antibody specific to the protein or 
the histone modification of interest. Purified DNA can be sequenced using different next-
generation sequencing platforms. On the Illumina Solexa Genome Analyzer (bottom left) 
clusters of clonal sequences are generated by bridge PCR, and sequencing is performed by 
sequencing-by-synthesis. On the Roche 454 and Applied Biosystems (ABI) SOLiD platforms 
(bottom middle), clonal sequencing features are generated by emulsion PCR and amplicons 
are captured on the surface of micrometre-scale beads. Beads with amplicons are then 
recovered and immobilized to a planar substrate to be sequenced by pyrosequencing (for 
the 454 platform) or by DNA ligase-driven synthesis (for the SOLiD platform). On single-
molecule sequencing platforms such as the HeliScope by Helicos (bottom right), fluorescent 
nucleotides incorporated into templates can be imaged at the level of single molecules, 
which makes clonal amplification unnecessary (adapted from Nature Reviews, Park 2009). 
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target genes has been an on-going struggle as majority of binding regions can be separated 
by hundreds of kilobases and in some cases megabases. In many cases the biological  
functionality of the TF binding is still unrevealed.  
Fullwood and colleagues have developed a technique called ChIA-PET (chromatin 
interaction analysis using paired-end tag sequencing) (Fullwood et al., 2009), which couples 
chromosome conformation capture (Dekker et al., 2002), a method for identifying interacting 
chromatin regions, with high-throughput sequencing. The authors found 689 ER-associated 
chromatin interaction complexes made up of duplexes and more complex interactions. 
These tend to involve stronger ER-binding events, which are biased toward specific histone 
marks and other transcriptional regulators more imperative for ER function. 
Endometrial cell lines seem to be less hormone responsive compared to MCF7. In our previous 
study we used ChIP-qPCR to identifying ER and PR targets in two endometrial cell lines. We 
found 137 target genes for ERs in HEC1A and 83 target genes for PRs in RL95-2 from 382 pre-
selected genes. The results confirmed the in vitro model of non-receptive (HEC1A) and 
receptive (RL95-2) endometrium in steroid hormone manner (Tamm et al., 2009).  
4.2 Expression analysis, RNA-Seq 
The transcriptome is the complete set of transcripts in a cell or tissue at a specific 
developmental stage or physiological condition. Expression microarrays are currently the 
most widely used methodology for transcriptome analysis. Breast cancer cell line MCF7 is 
most extensively used cell line in terms of studying E2 responsiveness and ER┙ localization. 
The number of genes which could be regulated by E2 has expanded extensively during the 
last decade from ~100 to ~1500  genes (Frasor et al., 2003, Carroll and Brown, 2006, Kininis 
et al., 2007, Levenson et al., 2002, Lin et al., 2004, Lin et al., 2007). It is likely that in the near 
future RNA-Seq, more sensitive technique, will introduce even more genes which show 
significant change in their activity after E2 or P4 treatment. Gene expression studies 
investigating endometrial receptivity using human biopsy samples have searched for genes 
differentially expressed in follicular and luteal phase (Kao et al., 2002; Carson et al., 2002; 
Riesewijk et al., 2003; Mirkin et al., 2005).  The highest number of regulatory genes was 
brought out in Carson´s study with 323 up-regulated and 370 down-regulated genes 
comparing follicular phase to the luteal phase. As mentioned before, the overlap of genes 
identified in different publications is relatively low. The difference could be due to 
variations is study design and limiting factors of microarray analysis. Microarray is 
hybridization-based approach, which involves incubating fluorescently labelled cDNA with 
custom made microarrays. Prominent limitations with this method include hybridization, 
cross-hybridization artefacts, different data analysis and low coverage of all possible genes 
in large genomes (Casneuf et al., 2007). Comparing expression levels across different 
experiments is often difficult and requite complicated normalization methods. The newer 
and potentially more comprehensive way to measure the whole active transcriptome is by 
direct ultra-high-throughput sequencing named RNA-Seq. The resulting sequence reads are 
individually mapped to the source genome and counted to obtain the number and density 
of reads corresponding to RNA from each known exon, splice event or new candidate gene 
(Mortazavi et al., 2008). RNA-Seq uses recently developed deep-sequencing technologies 
where RNA is converted to a library of cDNA fragments with adaptors attached to one or 
both ends. Each molecule is sequenced from single end or paired end. The reads are typically 
30-400bp, depending on the DNA-sequencing technology used. Similarly to ChIP extracted   
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Fig. 7. RNA-Seq method. a) Paired cDNA fragments are mapped to genome using TopHat 
software b) Each pair of fragment is treated as a single alignment and the abundances of the 
aasembled transcripts are estimated (b-e). First the fragments from distinct spliced mRNA 
isoforms are identified (b). Isoforms are then assembled from the overlap graph (c) and 
transcript abundance is estimated (d). Cufflinks estimates transcript abundances using a 
statistical model in which the probability of observing each fragment is a linear function of 
the abundances of the transcripts from which it could be originated. The program 
numerically maximizes a function that assigns a likelyhood to all possible sets of relative 
abundances of different isoforms (e), producing the abundances that best explain the 
observed fragments (adapted from Trapnell et al., 2010). 
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RNA can be used with Illumina, Applied Biosystems SOLIiD and Roche 454 Life Science 
platforms (Wang et al., 2009, Rev). RNA-Seq has very low, if any, background signal 
because cDNA sequences can be mapped to unique regions of the genome. It does not have 
any upper limit of quantification like DNA microarrays which lack sensitivity for genes 
expressed either at low or very high levels. Like other HTP Sequencing technologies, RNA-
seq faces several bioinformatics challenges in data processing. 
The analysis of RNA-Seq data starts from raw cDNA sequences, usually having lengths of 
40-70bp, depending on the platform. The general goal is to find which sites in human 
genome the RNA was transcribed from and determine the expression levels of these 
transcripts. Additionally, RNA-Seq data can be used to study expression levels of alternative 
splicing isoforms.  
The usual analysis consists of three main steps: 
1. Map each RNA sequence to the human genome. Mapping program has to enable 
spliced alignments because the sequences can come from separated exons. For this a 
fast and open source tool TopHat can be used (Trapnell et al., 2009) 
2. Count mappings to every site and measure the expression level of the sites. The 
expression level is usually measured in Fragments Per Kilobase of exon per Million 
fragments mapped (FPKM) which permits comparison of results across experiments. 
FPKM of a site shows how frequently the mapped fragments fall on that site. This 
analysis is possible using Cufflinks software, which can measure FPKM for whole genes 
and also for specific spliced isoforms (Trapnell et al., 2010) 
3. Compare experiments and find genes (or spliced isoforms) that have statistically 
significant different FPKM across experiments. This is also possible using commercial 
or open source software as Cufflinks. 
More detailed explanation of the analysis is depicted in the Figure 7.  
5. Conclusion  
This chapter summarised the current knowledge of E2 and P4 action in human 
endometrium and mammary gland. To understand both sides of steroid hormone action - in 
normal physiology and especially in pathology it is important to understand the molecular 
intracellular events of E2 and P4 in tissue-type manner. The same hormones could have 
different or even opposite effects in different tissues. Thus, attention should be applied to 
steroid hormones’ or their analogues’ possible side effects before using them in clinical 
treatments. Questions still remain about the aberrations of the endometrium leading to 
implantation failure, endometriosis and other dys-regulations. Even though studies of 
breast cancer development continuously unravel new information about the mechanisms 
leading from normal to malignant tissue proliferation, breast cancer is still the most fatal 
cancer type among women. The number of couples seeking for aid to achieve fertility is 
constantly increasing and thus a better understanding of factors needed for successful 
treatment and possible side effects is crucial. 
We would like to punctuate the importance of the next generation sequencing technologies 
which we believe are the key in understanding hormone dependent action in whole 
organism. With today´s knowledge of nearly entire human genome sequence and the 
development of new technologies based on HTP sequencing it has become possible to define 
all targets for the TF in vivo and establish entire transcriptome in a single experiment. Data 
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analysis is still complicated in a way and needs excellent computational skills but the data 
collected today will become the knowledge of tomorrow. 
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